NVS - Calliditas Therapeutics Seeks U.S. Capital Via IPO
Quick Take
Calliditas Therapeutics AB (CALT) has filed to raise $75 million in an IPO of its ADSs representing common shares, according to an F-1 registration statement.
The company is developing drug treatments for renal and hepatic disease conditions.
CALT has produced promising Phase 2 trials results for its lead candidate.
When we learn the details about IPO pricing and valuation, I’ll provide an update.
Company & Technology
Stockholm, Sweden-based Calliditas was founded to focus on renal and hepatic diseases and is advancing a pipeline of treatments for IgA Nephropathy and primary biliary